Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have been assigned a consensus recommendation of “Hold” from the twenty ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $74.21.

Several brokerages have recently issued reports on IONS. Cantor Fitzgerald lowered their price objective on shares of Ionis Pharmaceuticals from $65.00 to $56.00 and set a “neutral” rating for the company in a research report on Thursday, March 26th. William Blair reaffirmed a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Friday, January 24th. ValuEngine cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Needham & Company LLC reiterated a “buy” rating and issued a $89.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 6th. Finally, Royal Bank of Canada started coverage on shares of Ionis Pharmaceuticals in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $71.00 price target for the company.

In related news, Chairman Stanley T. Crooke sold 15,000 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $45.17, for a total value of $677,550.00. Following the transaction, the chairman now directly owns 61,545 shares of the company’s stock, valued at approximately $2,779,987.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of IONS. Americana Partners LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $29,000. Chevy Chase Trust Holdings Inc. purchased a new position in Ionis Pharmaceuticals during the fourth quarter valued at $37,000. NWK Group Inc. purchased a new position in Ionis Pharmaceuticals during the fourth quarter valued at $39,000. Cornerstone Advisors Inc. lifted its position in Ionis Pharmaceuticals by 107.2% during the first quarter. Cornerstone Advisors Inc. now owns 663 shares of the company’s stock valued at $31,000 after buying an additional 343 shares during the period. Finally, Total Clarity Wealth Management Inc. bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 86.60% of the company’s stock.

Shares of IONS stock opened at $53.07 on Thursday. Ionis Pharmaceuticals has a 1 year low of $39.32 and a 1 year high of $73.09. The firm’s 50 day moving average is $53.06 and its 200-day moving average is $56.99. The firm has a market capitalization of $7.48 billion, a price-to-earnings ratio of 48.25 and a beta of 1.70. The company has a current ratio of 9.91, a quick ratio of 9.83 and a debt-to-equity ratio of 0.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.23). Ionis Pharmaceuticals had a return on equity of 12.50% and a net margin of 16.79%. The company had revenue of $133.00 million for the quarter, compared to analyst estimates of $161.59 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. Ionis Pharmaceuticals’s revenue for the quarter was down 55.2% on a year-over-year basis. On average, equities research analysts forecast that Ionis Pharmaceuticals will post -0.24 earnings per share for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Story: Calculating net profit and net profit margin ratio

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with's FREE daily email newsletter.